vTv Therapeutics financials
$30.00−1.70%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $1.0M | $0.00 | $2.0M | $4.0M | $6.4M | $2.8M | $12.4M | $291.0K | $634.0K |
| Gross profit | $0.00 | $1.0M | $0.00 | $2.0M | $4.0M | $6.4M | $2.8M | $12.4M | $291.0K | $634.0K |
| Gross margin | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$32.9M | -$24.2M | -$26.4M | -$22.5M | -$21.7M | -$11.9M | -$20.9M | -$19.8M | -$50.7M | -$55.0M |
| Net income | -$27.0M | -$18.5M | -$20.3M | -$19.2M | -$13.0M | -$8.5M | -$17.9M | -$8.7M | -$16.1M | -$16.4M |
| Net margin | — | −1815.3% | — | −949.7% | −324.3% | −132.5% | −648.1% | −69.6% | −5547.8% | −2579.2% |
| Diluted EPS | $-3.20 | $-3.20 | $-9.71 | $-9.98 | $-8.29 | $-7.20 | $-23.60 | $-27.60 | $-66.80 | $-68.40 |
| EBITDA | -$32.9M | -$24.1M | -$26.3M | -$22.4M | -$21.6M | -$11.8M | -$20.9M | -$19.6M | -$50.5M | -$54.8M |
| Operating cash flow | -$25.3M | -$25.3M | -$19.1M | -$16.0M | -$19.3M | -$18.0M | -$23.0M | -$26.9M | -$44.6M | -$48.2M |
| Free cash flow | -$25.3M | -$25.3M | -$19.1M | -$16.0M | -$19.3M | -$18.0M | -$23.1M | -$26.9M | -$44.6M | -$48.3M |
| Diluted shares | 8.4M | 5.8M | 2.1M | 1.9M | 1.6M | 1.2M | 0.8M | 0.3M | 0.2M | 0.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $88.9M | $36.7M | $9.4M | $12.1M | $13.4M | $5.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $191.0K | $224.0K | $256.0K | $84.0K |
| Total assets | $89.9M | $38.3M | $11.0M | $33.2M | $25.5M | $14.8M |
| Total liabilities | $25.5M | $24.0M | $29.6M | $27.4M | $10.3M | $11.0M |
| Shareholders' equity | $64.4M | $14.3M | -$24.7M | -$10.7M | -$9.7M | -$80.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology